Therapeutic Pipeline
SATOR Therapeutics has a portfolio of nearly 30 highly effective oncolytic viruses which are differentially effective across multiple cancers. The first virus which we will bring into the clinic is STR-0011 for the orphan indication of Mesothelioma. Subsequently, we will pursue STR-002 and STR-0013 for Mesothelioma followed by pursuing the indication of Glioblastoma. In parallel, we will develop our gating companion diagnostic approach and further develop our dendritic cell delivery approach.
Pipeline Approach
Ideally, we would go to market initially with 2-3 viruses for an application such as Glioblastoma where the viruses would be combined in a treatment paradigm to increase efficacy. However, this would require 2-3 CMC/IND processes and would not allow for a 'fast-track' designation whereas Mesothelioma would. Despite the use of a single virus and the challenges with neutralizing antibodies, the short survival (12 months) for Mesothelioma means that a single virus can have a meaningful impact on overall survival for patients.
The orphan indication of Mesothelioma simply allows SATOR to get its therapeutic platform into the market most quickly while potentially benefiting an underserved patient population. From this early win, SATOR can then target additional viruses and indications and, potentially, with use of 2-3 viruses, make an curable disease - curable.
